MetiMedi Co., Ltd.

MetiMedi, a bio pharmaceutical company based in South Korea, is at the forefront of cutting-edge research in immuno-oncology. The company is committed to developing a unique platform technology that addresses the unmet needs of solid cancer therapies and beyond. By targeting specific cellular metabolic reprogramming in tumor cells, MetiMedi's immunotherapy leads to tumor necroptosis and immune activation, with exceptional safety. Phase 2 clinical studies with METI-101 for refractory metastatic colorectal cancer have demonstrated efficacy and safety.